New drug tested for rare blood disorder when standard treatment fails
NCT ID NCT05972967
Summary
This study tested a new drug called OMS906 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. It specifically looked at patients who weren't getting good results from their current standard treatment, ravulizumab. Researchers gave 12 participants two different doses of OMS906 to check if it was safe and if it helped improve their blood counts and reduce symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Omeros Investigational Site
Aachen, Germany
-
Omeros Investigational Site
Ulm, Germany
-
Omeros Investigational Site
Thessaloniki, Greece
-
Omeros Investigational Site
Lausanne, Switzerland
-
Omeros Investigational Site
Leeds, United Kingdom
Conditions
Explore the condition pages connected to this study.